Furthermore, future studies should perform randomized controlled trials assessing the efficacy of anti-inflammatory therapies in the prevention of CI-AKI, including perioperative use of anti-inflammatory drugs such as sodium-glucose cotransporter-2 (SGLT-2) inhibitors [49] and colchicine. This evidence concerns the gene SLC5A2 and acute kidney injury.